Halozyme Therapeutics

Yahoo Finance • 11 days ago

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story

Yahoo Finance • 14 days ago

One of the market's hottest stock themes is buying everything AI can't replace

As investors worry about all of the companies that AI will wipe out, they are rotating into the ones that AI will have a harder time disrupting. And the HALO trade, as it is called, is working. HALO, which stands for "heavy assets, low ob... Full story

Yahoo Finance • 20 days ago

After-Hours Earnings Report for May 11, 2026 : SPG, ASTS, STE, OVV, ACM, HALO, SGHC, HIMS, RGTI, IFS, NOVT, MARA

The following companies are expected to report earnings after hours on 05/11/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Simon Property Group, Inc. (SPG)is reporting for the quarter ending March 31,... Full story

Yahoo Finance • 22 days ago

A Look At Halozyme Therapeutics (HALO) Valuation After Recent Share Price Swings

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Halozyme Therapeutics (HALO) is back on investors’ radar after rec... Full story

Yahoo Finance • 23 days ago

Stocks Finish Higher on Solid Earnings and a Resilient Labor Market

The S&P 500 Index ($SPX) (SPY) on Friday closed up +0.84%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.02%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +2.35%.  June E-mini S&P futures (ESM26) rose +0.79%, and June E-m... Full story

Yahoo Finance • 29 days ago

Halozyme (HALO) Rated Buy on Strong Royalty Growth

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Hal... Full story

Yahoo Finance • 29 days ago

How Investors Are Reacting To Halozyme Therapeutics (HALO) Hiring Big-Pharma Veteran Darren Snellgrove As CFO

Halozyme Therapeutics recently announced that Darren Snellgrove, a veteran finance leader with more than 30 years of biopharma experience including senior roles at Johnson & Johnson, will become its Chief Financial Officer on June 8, 2026,... Full story

Yahoo Finance • last month

Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV). Over the next few years, therap... Full story

Yahoo Finance • 2 months ago

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

SAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and licen... Full story

Yahoo Finance • 2 months ago

Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued growth stocks to buy, according to analysts. On March 12, Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the appointment of David Ramsay as the interim Chief Fin... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index down 1.3% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression‑free survival and overall survival versus standard of care regimens SAN DIEGO, March 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc... Full story

Yahoo Finance • 3 months ago

Halozyme Therapeutics, Inc. (HALO): A Bull Case Theory

We came across a bullish thesis on Halozyme Therapeutics, Inc. on 24K Research’s Substack. In this article, we will summarize the bulls’ thesis on HALO. Halozyme Therapeutics, Inc.'s share was trading at $70.98 as of February 20th. HALO’s... Full story

Yahoo Finance • 3 months ago

2 Reasons to Like HALO (and 1 Not So Much)

Since August 2025, Halozyme Therapeutics has been in a holding pattern, posting a small loss of 2.1% while floating around $70.71. The stock also fell short of the S&P 500’s 6.2% gain during that period. Is now the time to buy HALO? Or do... Full story

Yahoo Finance • 3 months ago

Halozyme (HALO) Loses 9% on Weak Earnings

We recently published 10 Losing Stocks in an Otherwise Optimistic Market. Halozyme Therapeutics Inc. (NASDAQ:HALO) was one of the worst performers on Wednesday. Halozyme snapped a two-day winning streak on Wednesday, shedding 9.01 percent... Full story

Yahoo Finance • 3 months ago

Halozyme Therapeutics Inc (HALO) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...

This article first appeared on GuruFocus. Total Revenue: $1.4 billion, a 38% increase year-over-year. Royalty Revenue: $867.8 million, a 52% increase year-over-year. Net Income: $316.9 million, compared to $444.1 million in 2024. Adjusted... Full story

Yahoo Finance • 3 months ago

Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline

Earnings Call Insights: Halozyme Therapeutics (HALO) Q4 2025 MANAGEMENT VIEW * Helen Torley, President and CEO, highlighted that "2025 was one of the most significant and value-creating years in Halozyme's history," citing the expansio... Full story

Yahoo Finance • 3 months ago

Halozyme (HALO) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Date Feb. 17, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Helen I. TorleyChief Scientific Officer — Chris WallChief Financial Officer — Nicole LaBrosse Takeaways Total revenue -- $1... Full story

Yahoo Finance • 3 months ago

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions of Elektrofi's Hypercon™ Technology and Surf Bio's Hyperconcentration T... Full story

Yahoo Finance • 3 months ago

Halozyme Therapeutics Q4 2025 Earnings Preview

* Halozyme Therapeutics (HALO [https://seekingalpha.com/symbol/HALO]) is scheduled to announce Q4 earnings results on Tuesday, February 17th, after market close. * The consensus EPS Estimate is $2.20 [https://seekingalpha.com/symbol/HA... Full story